By David B. Duggan, Gina R. Petroni, Jeffrey L. Johnson, John H. Glick, Richard I. Fisher, Joseph M. Connors, George P. Canellos, and Bruce A. Peterson
T HE TREATMENT OF Hodgkin's disease was revolution-
ized with the development of a regimen containing mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), which was the first drug regimen that produced a high proportion of complete remissions (CRs) and cure. 1 Bonadonna et al 2 subsequently introduced doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as a potentially curative salvage regimen for patients experiencing relapse after MOPP.
In 1992, the Cancer and Leukemia Group B (CALGB) reported a trial comparing MOPP, ABVD, or alternating MOPP/ ABVD for advanced Hodgkin's disease. 3 ABVD and MOPP/ ABVD produced similar CR (81% and 82%, respectively) and failure-free survival (FFS) rates (64% for both at 3 years). Furthermore, both ABVD regimens were superior to MOPP (69% CR and 48% FFS at 3 years). There were no differences in overall survival (OS).
In 1985, Klimo and Connors 4 reported results of the MOPP/ ABV hybrid, which produced an 83% CR rate to the chemotherapy and a 73% 5-year FFS rate, including those who received adjuvant radiotherapy (RT). At the time the current trial was planned, randomized trials comparing MOPP/ABV hybrid with both sequential (MOPP 3 ABVD) and alternating (MOPP/ ABVD) therapy had recently begun. The results of these trials demonstrate that MOPP/ABV hybrid is equally effective as alternating MOPP/ABVD and more effective than sequential MOPP 3 ABVD. 5, 6 Therefore, the current trial comparing MOPP/ABV hybrid and ABVD can be seen as a conclusion to a sequence of comparisons over nearly two decades.
The risk-to-benefit ratio of therapy for Hodgkin's disease must be assessed over a long time because serious treatment-related toxicity may develop many years after therapy. MOPP causes myelodysplasia (MDS), acute leukemia, sterility, and neuropathy. 3, 7 Doxorubicin and bleomycin, components of ABVD, may cause cardiomyopathy and pulmonary fibrosis. 3, 7 All of these are of concern with the MOPP/ABV hybrid. Because the MOPP/ ABV hybrid was effective and widely used despite the absence of controlled trials comparing it with a less toxic regimen, this trial was designed to compare both the therapeutic benefit and toxicity of the hybrid regimen with that of ABVD alone.
PATIENTS AND METHODS

Patient Selection
Adult patients with histologically confirmed stage III 2 A, IIIB, or IV Hodgkin's disease or who had experienced relapse after definitive RT were eligible. Entry requirements included at least one measurable lesion, granulocytes Ն 1,800/L, platelets Ն 100,000/L, hemoglobin Ն 10 g/dL, creatinine Յ 2 mg/dL, and bilirubin Յ 1.5 times the upper limit of normal. Patients with laboratory abnormalities ascribed to Hodgkin's disease were considered eligible. Left ventricular ejection fraction (LVEF) of at least 50%, a diffusing capacity for carbon monoxide (DLCO) and forced expiratory volume in 1 second of at least 50% of predicted, and a performance status of 0 to 2 (CALGB scale) were required. Central pathology review of all diagnostic biopsies was required.
Staging included a history and examination; computed tomography (CT) scan of the chest, abdomen, and pelvis; and a lymphangiogram if the CT scan of the abdomen was equivocal. Laparotomy was required if the CT scan and lymphangiogram were not definitive. Bone marrow aspirate and biopsy were required. A gallium scan was recommended but not required. Patients who had received prior cytotoxic chemotherapy, had a history of a malignancy, were pregnant, or had serious illness that would limit survival or prevent informed consent were excluded. All patients were required to give written informed consent, and the protocol was approved by the institutional review board at each institution.
A chest x-ray and CT scan measurements of tumor response were taken at least every three cycles. LVEF and spirometry with DLCO were repeated after four cycles. RT was not permitted. The use of prophylactic hematopoietic growth factors was not permitted.
Study Administration, Treatment, and Monitoring
The study was coordinated by the CALGB with participation of the Eastern Cooperative Oncology Group, Southwest Oncology Group, and the National Cancer Institute of Canada Clinical Trials Group. Patients were stratified by age (Ͻ 40 or Ն 40 years), stage, and whether they had previously received RT. Randomization was performed using a block design within the 12 strata. ABVD or MOPP/ABV hybrid was given with doses and dose modifications as previously described. 3, 4 Responding patients received treatment to the attainment of clinical complete response (CCR) plus an additional two cycles, for a minimum of eight cycles and a maximum of 10 cycles. Protocol therapy was discontinued if LVEF decreased by 15% from baseline or to less than 45%, if congestive heart failure or cardiomegaly appeared, or if a persistent new arrhythmia developed. Bleomycin was discontinued if the forced expiratory volume in 1 second or DLCO decreased to less than 50% of predicted or if clinical signs of pulmonary toxicity appeared.
The trial was designed to enroll 900 patients, and an independent Data and Safety Monitoring Board evaluated interim analyses of treatment efficacy and toxicity twice each year. Early closure of the study was planned if statistically significant differences between treatment regimens appeared at any interim analysis, 8 using group sequential methodology with a continuous use function to determine the rate at which type I error was spent. 9 The Lan and DeMets 10 analog to the O'Brien and Fleming 11 boundaries was used.
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In November 1995, the Data and Safety Monitoring Board observed an increased number of treatment-related deaths and secondary malignancies on the MOPP/ABV arm. The trial was then closed, after accruing 856 of a planned sample of 900 patients. Investigators received notification that increased toxicity for patients on the MOPP/ABV arm had been observed, but no OS difference was demonstrated, and it was left to their discretion how to proceed with patients currently receiving therapy.
Statistical Analysis
The results are presented from an analysis based on intention to treat. Of the 856 patients who were registered, all are included in the analysis, with the exception of four patients (two on each arm) who were withdrawn from the study before any treatment was given (we have no data for these patients). Six patients were switched from MOPP/ABV to ABVD when the preliminary results were announced and are analyzed as initially randomized. Twenty-two patients (eight receiving ABVD and 14 receiving MOPP/ABV) were determined to have had non-Hodgkin's lymphoma after central pathology review. Seventy-six patients (39 receiving ABVD and 37 receiving MOPP/ABV) did not meet all eligibility requirements, but most violations were minor. Analyses that excluded those who switched arms, had nonHodgkin's lymphoma, or who did not meet all eligibility criteria were also performed. Similar results were obtained for the two analyses; therefore, the results of the intention-to-treat analysis are reported. Some patients received RT while in partial remission after chemotherapy in violation of the protocol specifications. We did not count as CRs those who improved after RT, nor did we count them as treatment failures caused by additional therapy or censor them at the time of RT. Similarly, we did not exclude patients who received granulocyte colony-stimulating factor, and we ignored those treatment violations in this intention-to-treat analysis.
The sample size was designed to provide 90% confidence of determining a 10% difference in the cure rates (ABVD, 65%; MOPP/ABV, 75%), testing at the one-sided 5% level of statistical significance. Although the study was designed with a one-sided 5% significance level for the major end points, all reported P values correspond to a two-sided test of significance.
Categorical data (toxicity and response) were analyzed using the 2 test for contingency tables 13 using exact significance levels. FFS was measured from registration on study to evidence of first progression, relapse or recurrence, death from any cause, or discontinuation of treatment for nonresponders. Survival was measured from registration to death from any cause. Time to event distributions (FFS and survival) were estimated using the product-limit method of Kaplan and Meier.
14 Formal tests using time-dependent covariables and Schoenfeld residuals were used to test the assumptions of proportional hazards. 11 The statistical significance of differences observed in time-to-event distributions was assessed using the log-rank test.
14 Analyses were performed using SAS (Version 8.1; SAS Institute, Inc, Cary, NC) and graphics were generated using S-Plus (Version 4.5; Mathsoft, Seattle, WA).
Response criteria defined a CR as the absence of symptoms, physical findings, or imaging evidence of Hodgkin's disease. A repeat bone marrow biopsy must have been negative if initially positive. A CCR was defined as the absence of symptoms or physical findings, with CT scans demonstrating a greater than 50% reduction of the product of perpendicular diameters of measurable lesions in the chest and a greater than 80% reduction in the product of perpendicular diameters of measurable lesions in the abdomen persisting over two cycles of treatment. To qualify as a CCR, gallium scans were required to be negative in the mediastinum if they had been initially positive. In the analysis presented here, the patients achieving CR or CCR are pooled into the overall CR category. If a patient did not achieve CR or CCR after eight cycles, they were to be removed from protocol-directed therapy. A partial response was defined as a greater than 50% but less than 80% reduction in the sum of the perpendicular diameters of lesions in the abdomen or a persistently positive gallium scan regardless of tumor measurements. Disease progression was defined as the appearance of new sites of disease or a greater than 25% increase in the sum of the products of the perpendicular directions of measurable disease. Stable disease was defined as a less than 50% reduction in the sum of the products of perpendicular diameters of any site of measurable disease (ie, nonresponder). Patients for whom follow-up measurements are unavailable are considered nonassessable. Toxicity was graded according to the National Cancer Institute common toxicity criteria.
patients meeting all eligibility criteria, the overall CR rate is 80%, with no difference between treatment arms. Nine patients receiving ABVD and eight patients receiving MOPP/ABV developed progressive disease while receiving treatment.
FFS and OS are shown in Fig 1. FFS at 5 years was 63% (95% confidence interval [CI], 59% to 68%) after ABVD and 66% (95% CI, 61% to 70%) after MOPP/ABV (log-rank P ϭ .42). OS at 5 years was 81% for all patients, 82% (95% CI, 79% to 86%) after ABVD, and 81% (95% CI, 78% to 85%) for MOPP/ABV (log-rank P ϭ .82). When survival analysis was limited to the patients who met all eligibility criteria, the 5-year survival rate was 81% (95% CI, 79% to 84%) with no difference between treatment arms.
We examined the effect of predefined stratification criteria (stage, age, and previous RT) on response rates, toxicity, and survival. The rate of attaining a CR for the entire cohort did not vary with stage or whether there had been previous RT, but did vary with age. Eighty-one percent of patients younger than 40 years old obtained a CR compared with 74% of patients 40 years of age or older (P ϭ .01). There was no difference in response rate by treatment arm in any stratum. Similarly, FFS and OS were related to age (P Ͻ .001), and increased stage of disease and patients who had experienced relapse were at increased risk of failure for FFS and OS (P ϭ .055 and P ϭ .030, respectively), but there was no significant difference between treatment arms.
Hasenclever et al 15 identified seven predictive factors for FFS in Hodgkin's disease: albumin less than 4 g/L, hemoglobin less than 10.5 g/L, male sex, age Ն 45 years, stage IV, WBC count Ն 15,000/mL, and lymphocytopenia (Ͻ 600/mL or 8% of WBCs). We did not plan an analysis on the basis of these factors at the time the protocol was written but have abstracted these data on 566 patients and determined their FFS on the basis of their prognostic scores. We excluded patients from our analysis who had received previous RT because the Hasenclever analysis only studied patients who were initially treated with chemotherapy. Furthermore, our protocol excluded patients with a poor performance status, impaired vital organ function, or a hemoglobin level of less than 10.5 g/L, and the Hasenclever analysis included patients treated with many different chemotherapies, including MOPP, such that precise comparisons are not appropriate. Our patients experienced an overall 5-year FFS of 73% (95% CI, 70% to 77%), as compared with 66% reported in the Hasenclever analysis. The FFS at 5 years of our patients on the basis of the number of prognostic factors is listed in Table 3 . Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP/ABV, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine. Acute toxicity data are listed in Table 4 (top) and include reported toxicity beginning with the first treatment until 30 days after the last chemotherapy was given. Data for acute toxicity were submitted for 814 of the 852 patients (412 of the 424 ABVD patients and 402 of the 410 MOPP/ABV patients). For this analysis we have combined grade 2 to 5 pulmonary toxicity described in the National Cancer Institute common toxicity criteria, including dyspnea, partial pressure of oxygen/carbon dioxide, DLCO, fibrosis, pneumonitis, acute respiratory distress syndrome, or other pulmonary, because an observation of any of these levels of toxicity was specified in the protocol to require suspension of bleomycin treatment and was considered to be clinically significant. Similarly, cardiac toxicity includes grade 2 to 5 dysrhythmias and cardiac function, which also would have led to protocol-specified cessation of doxorubicin therapy, which was deemed clinically significant. Hematologic toxicity was also pooled for comparison and included grades 3 to 5 (severe, life-threatening, or lethal) toxicity, which were considered clinically significant.
There were 15 deaths during initial therapy on the MOPP/ ABV arm and nine on the ABVD arm (P ϭ .057). Approxi- mately three quarters of these deaths were in patients older than 55 years. There was a significantly increased rate of pulmonary toxicity in patients 40 years of age and older compared with younger patients (38% and 22%, respectively; P Ͻ .001). Forty-six percent of those older than 40 years who received MOPP/ABV developed pulmonary toxicity, compared with 30% on the ABVD arm (P ϭ .068). The use of previous RT was associated with a 38% chance of pulmonary toxicity, compared with those with no prior RT, who had a 25% chance (P ϭ .014). There was no effect of chemotherapy arm on the rate of pulmonary toxicity within the groups who received RT or not. There was no difference between treatment arms in the observed rate of acute cardiac toxicity. MOPP/ABV was associated with an increased risk of hematologic toxicity, including life-threatening or lethal neutropenia, anemia, thrombocytopenia, or infection (P Ͻ .001). MOPP/ABV was also associated with a significantly increased incidence of severe malaise, fatigue, anorexia, and hypotension (all P Ͻ .01). There were no other categories of toxicity with a significant difference between treatment arms.
Delayed toxicity data, which include all reported toxicity occurring more than 30 days after the completion of chemotherapy, are listed at the bottom of Table 4 . Toxicity data for this period have been submitted for 610 patients (300 ABVD patients and 310 MOPP/ABV patients). For this period, pulmonary and cardiac toxicity are defined as the number of patients with any grade 2 to 5 toxicity. During the 6-year interval after cessation of therapy, there has been one additional report of the development of congestive heart failure (patient who received ABVD) and no reports of new pulmonary toxicity, although some toxicity first manifested during treatment did not resolve.
After a median follow-up of 6 years, 46 second malignancies have been recorded, 18 in patients treated with ABVD and 28 in patients treated with MOPP/ABV (P ϭ .13). There have been 11 cases of MDS or acute myelogenous leukemia (AML) in patients randomized to the hybrid arm and two among patients randomized to ABVD (P ϭ .011). There was no relationship between age or the use of previous RT on the rate of development of MDS or AML. The two patients who developed AML or MDS after being randomly assigned to ABVD were subsequently treated with MOPP-containing regimens and RT; one of the two also received additional alkylator-based chemotherapy and autologous bone marrow transplantation before the diagnosis of AML was established. No patient who received only ABVD developed MDS or AML. There were several additional secondary tumors observed; none were significantly more frequent on either arm. NOTE. Numbers of patients are as follows: for toxicity during initial treatment, n ϭ 412 for ABVD and n ϭ 402 for MOPP/ABV; for toxicity after completion of treatment, n ϭ 300 for ABVD and n ϭ 310 for MOPP/ABV.
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP/ABV, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine. * 2 test using exact significance levels. †Grade 2 or greater dyspnea, partial pressure of oxygen/carbon dioxide, diffusing capacity for carbon monoxide, fibrosis, acute respiratory distress syndrome, noninfectious pneumonitis, cardiac function, or arrhythmia, all of which would result in dose modification or elimination of doxorubicin or bleomycin according to protocol specifications. ‡Maximum toxicity grade 3 or greater, severe, life-threatening, or fatal.
Causes of death are listed in Table 5 . Of the 190 deaths observed, 105 (55%) were caused by Hodgkin's disease and 40 (21%) were caused by complications of initial treatment.
DISCUSSION
This trial compared ABVD and the MOPP/ABV hybrid regimen as initial therapy for advanced Hodgkin's disease. The data demonstrate a striking similarity in the OS and FFS of patients on either arm after 6 years of follow-up. Given the low relapse rates for Hodgkin's disease after 5 years of remission in previous trials of ABVD or MOPP/ABV, it seems unlikely that significant FFS or OS advantages will emerge within the next several years of observation.
However, there are statistically significant and clinically important differences in both the toxicity and secondary malignancies observed with these two therapies. The MOPP/ABV hybrid caused significantly more acute hematologic and pulmonary toxicity (Table 4) . MOPP/ABV also caused significantly more fatigue, anorexia, and nausea. The MOPP/ABV hybrid was associated with a higher rate of treatment-related deaths, but this was not statistically significant (P ϭ .105). Many of the toxic deaths on the MOPP/ABV arm were due to pulmonary failure, and it is difficult to determine whether infection or drug toxicity was the primary insult; in many patients, both likely contributed to death. Moreover, many patients were neutropenic at the time they developed pulmonary infiltrates. Nevertheless, although the exact pathophysiology may be uncertain, the direct attribution of death to treatment-related toxicity is clear. It is not clear why there is increased pulmonary toxicity on the MOPP/ABV arm, which delivered a lower total dose of bleomycin than did ABVD. There were significantly more patients receiving MOPP/ABV who experienced pulmonary toxicity that necessitated dose adjustment or elimination of bleomycin.
We chose to withdraw bleomycin therapy for any clinical sign or symptom of pulmonary toxicity, or an asymptomatic decrement in DLCO, yet significant rates of serious pulmonary toxicity were observed. It may be that a lower threshold for DLCO decrement would be appropriate for withholding bleomycin, or that bleomycin pulmonary toxicity is unpredictable by standard evaluation methods; nevertheless, careful consideration must be given to future studies to identify better predictive tools and alternative regimens that do not contain bleomycin, and physicians must maintain a high degree of vigilance when monitoring patients receiving bleomycin for the development of pulmonary toxicity.
In sum, MOPP/ABV caused more life-threatening side effects than ABVD during the initial treatment phase. ABVD did not cause any acute toxicity more frequently than MOPP/ABV. Most striking is the increased incidence of second malignancies seen with the MOPP/ABV hybrid, especially the increased incidence of MDS and secondary acute leukemia. Several studies have linked the use of chemotherapy, notably alkylator-based regimens, to the development of MDS or acute leukemia, especially when used in combination with RT. [16] [17] [18] [19] These reports describe an overall risk of 2.5% to 9% of developing acute leukemia or MDS, which becomes apparent within 1 year of diagnosis and remains elevated for at least 9 years before declining. Our data are quite consistent with these studies, demonstrating an increased incidence of MDS or leukemia after MOPP and a substantially smaller or nonexistent risk with ABVD. 20, 21 Because this report is based on an average follow-up period of only 7 years, it is likely that additional cases of MDS or leukemia will be reported. However, it is noteworthy that a previous intergroup trial comparing sequential MOPP 3 ABVD to the MOPP/ABV hybrid reported one case of AML among the 367 patients treated with MOPP/ABV hybrid after a median follow-up period of 7.3 years. 5 This important discrepancy in the rate of AML or MDS associated with the MOPP/ABV hybrid is unexplained.
One of the great concerns regarding the ABVD regimen has been the potential for development of doxorubicin cardiomyopathy. In this trial, the rate of drug discontinuation for cardiac toxicity during the treatment phase was not different in either arm, nor was there a difference in the rate of development of congestive heart failure after 6 years of follow-up.
This trial specified that patients receive a minimum of eight cycles of chemotherapy to recapitulate the duration of treatment described in the original study of MOPP/ABV. The appropriate duration of therapy cannot be ascertained from this trial.
A series of randomized clinical trials in North America have compared ABVD versus MOPP/ABV (current trial), alternating MOPP/ABVD versus MOPP or ABVD alone, sequential MOPP 3 ABVD (three cycles each) versus the MOPP/ABV hybrid program, and alternating MOPP/ABVD versus MOPP/ABV hybrid ( Table 6 ). The MOPP/ABV hybrid has been equal or superior to the alternating MOPP/ABVD and sequential MOPP 3 ABVD regimens. ABVD has been demonstrably superior to MOPP in two randomized trials, the CALGB trial and in a comparison of MOPP versus ABVD, each given with RT, for patients with bulky stage II disease. 6 The MOPP/ABV hybrid has also been demonstrated to be equal or superior to MOPP 3 ABVD and MOPP/ABVD. In the current trial, ABVD has been shown to be as effective as MOPP/ABV, but less toxic. The natural conclusion of this series of randomized trials is that ABVD alone is at least as effective, and less toxic, than any of the MOPP-containing regimens or hybrids noted above.
Two other treatment regimens are under careful clinical study. The German Hodgkin's Study Group has studied bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) and has compared the combination of BEACOPP plus RT with a regimen of cyclophosphamide, vincristine, procarbazine, and prednisone/ABVD plus RT; a significant increase in FFS and OS for the BEACOPP regimen was demonstrated. 22 The rate of MDS or secondary leukemia with BEACOPP was low; only two of 457 patients receiving BEACOPP developed MDS or secondary leukemia after 3 years of follow-up. The Stanford V regimen represents a different approach to the treatment of Hodgkin's disease. The Stanford V regimen includes lower cumulative doses of doxorubicin and bleomycin than ABVD, gives mechlorethamine on three occasions but no procarbazine, and completes chemotherapy in 12 weeks, after which patients receive 36 Gy of RT to sites of initial disease Ն 5 cm or macroscopic splenic disease. One hundred forty-two patients with bulky stage I and stage II, III, or IV Hodgkin's disease were treated with Stanford V, with a 5.6-year freedom-from-progression rate of 89% and an OS of 96% reported, and no secondary leukemia observed. 23 This regimen is currently being compared with ABVD. A second pilot study of this in 45 patients resulted in a 15-year estimated freedom-from-progression rate of 85% and a single case of leukemia. 24 In summary, we conducted a randomized clinical trial comparing ABVD with the MOPP/ABV hybrid and demonstrated that the FFS and OS of these regimens are similar, yet there is increased acute toxicity with the MOPP/ABV hybrid, as well as an increased risk of secondary hematologic malignancies and solid tumors. We conclude that ABVD should be considered the standard regimen for the treatment of advanced Hodgkin's disease and should be the regimen against which new treatments are evaluated.
